Abevmy Injection is administered only as an intravenous (IV) infusion. It should be given following the surgical incision has fully healed. The first infusion is given over 90 minute and the subsequent infusion should be given over 60 minutes in case first infusion is tolerated. All the subsequent infusions should be administered over 30 minutes in case infusion over 60 minutes is tolerated.
Most common side effects include High blood pressure, Inflammation of the nose, Headache, Rectal bleeding, Taste change, Nosebleeds, Dry skin, and Protein in the urine.
- Discontinue bevacizumab dosage in patients with the fistula formation involving an internal organ.
- Serious/Fatal gastrointestinal perforation may occur at a higher incidence in patients treated with this drug.
- Do not use this medicine to patients with the recent history of hemoptysis of ≥1/2 teaspoon of red blood.
- Avoid bevacizumab uses for 28 days after major surgery and until the surgical wound is fully healed.
- Nursing or bevacizumab should be discontinued, taking into account the importance of the drug to the mother.
- Patients should be advised to undergo routine blood pressure monitoring and to contact their health care provider in case of blood pressure is elevated.
- Infusion should be stopped if a severe infusion reaction developed and appropriate medical therapy should be administered.
Care should be exercised in the handling of ABEVMY. ABEVMY injections should not be opened, freezed or shaken. Stores permitted between 2−8°C (36−46°F). Vials should be protected from the light.
WHAT IS BEVACIZUMAB AND WHAT IT IS USED FOR:
ABEVMY is an angiogenesis inhibitor, indicated for the treatment of:
Non-small cell lung cancer
Cancer of colon and rectum